25 Results for "

trypanothione

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "trypanothione" in MCE Product Catalog:

Cat. No.: HY-114734
CAS No.: 2095-21-8
Target:  

Parasite

Research Areas:  

Infection

Didesmethylpromazine (Compound 18) is a trypanothione reductase inhibitor with an I50of 1412  μM against T. cruzi trypanothione reductase. Didesmethylpromazine can be used in the research of trypanosome and leishmania infections .
loading...
    loading...
Cat. No.: HY-181516
Target:  

Parasite

Research Areas:  

Infection

Anti-Trypanosoma cruzi agent-8 is an anti-Trypanosoma agent and also a Trypanosoma cruzi trypanothione reductase (TcTR) inhibitor, with an IC50 of 3.9 μM against TcTR. Anti-Trypanosoma cruzi agent-8 functionally inhibits the enzymatic activity of TcTR. Anti-Trypanosoma cruzi agent-8 exhibits trypanocidal activity against intracellular Trypanosoma cruzi amastigotes .
loading...
    loading...
Cat. No.: HY-P12260
CAS No.: 3027489-02-4
Research Areas:  

Cancer

AJICAP reagent 1b is a thiophenyl ester-based site-specific conjugation reagent for antibody modification applications. AJICAP reagent 1b is used in HER2-positive gastric cancer-related research .
loading...
    loading...
Cat. No.: HY-P12261
Research Areas:  

Cancer

AJICAP reagent 6b is an Fc-affinity peptide reagent that site-specifically modifies Lys288 of native antibodies via thiophenyl ester chemistry. AJICAP reagent 6b enables site-specific conjugation of native antibodies at Lys288 with high conversion yield and reduced aggregation. AJICAP reagent 6b can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-B0670S
Dihydroergotamine-d3 is the d3-labeled Dihydroergotamine (HY-B0670). Dihydroergotamine (DFN-19) is a blood-brain barrier-permeable semi-synthetic ergot alkaloid, acting as a full agonist of 5-HT1B/1D receptors (Ki values of 0.3 nM and 2.5 nM, respectively; functional IC50 values of 2 nM and 2.2 nM, respectively). Dihydroergotamine inhibits Forskolin (HY-15371)-stimulated cAMP accumulation, possesses α-adrenergic receptor antagonistic activity and weak dopaminergic agonistic activity. It mediates intracranial cerebrovascular contraction, inhibits the release of neuropeptides such as CGRP/substance P, and suppresses neurogenic inflammation by activating 5-HT1B/1D receptors in the trigeminovascular system. Dihydroergotamine binds to the catalytic site of Trypanosoma cruzi trypanothione reductase and exhibits trypanocidal activity in vitro. Dihydroergotamine can be used in studies related to migraine and trypanosome infections .
loading...
    loading...